Addition of Docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness

Woods, Beth S., Sideris, Eleftherios, Sydes, Matthew R., Gannon, Melissa R., Parmar, Mahesh K.B., Alzouebi, Mymoona, Attard, Gerhardt, Birtle, Alison J., Brock, Susannah, Cathomas, Richard, Chakraborti, Prabir R., Cook, Audrey, Cross, William R., Dearnaley, David P., Gale, Joanna, Gibbs, Stephanie, Graham, John D., Hughes, Robert, Jones, Rob J., Laing, Robert, Mason, Malcolm D., Matheson, David, McLaren, Duncan B., Millman, Robin, O'Sullivan, Joe M., Parikh, Omi, Parker, Christopher C., Peedell, Clive, Protheroe, Andrew, Ritchie, Alastair W.S., Robinson, Angus, Russell, J. Martin, Simms, Matthew S., Srihari, Narayanan N., Srinivasan, Rajaguru, Staffurth, John N., Sundar, Santhanam, Thalmann, George N., Tolan, Shaun, Tran, Anna T.H., Tsang, David, Wagstaff, John, James, Nicholas D. and Sculpher, Mark J. 2018. Addition of Docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. European Urology Oncology 1 (6) , pp. 449-458. 10.1016/j.euo.2018.06.004

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (866kB) | Preview

Official URL: http://dx.doi.org/10.1016/j.euo.2018.06.004

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
ISSN:	2588-9311
Date of First Compliant Deposit:	1 August 2019
Date of Acceptance:	12 June 2018
Last Modified:	30 Nov 2019 06:28
URI:	http://orca.cf.ac.uk/id/eprint/124638

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item